All Trans Retinoic Acid, Transforming Growth Factor β and Prostaglandin E₂ in Mouse Plasma Synergize with Basophil-Secreted Interleukin-4 to M2 Polarize Murine Macrophages

Victor W. Ho, Elyse Hofs, Ingrid Elisia, Vivian Lam, Brian E. Hsu, June Lai, Beryl Luk, Ismael Samudio, Gerald Krystal*

The Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, British Columbia, Canada

☯ These authors contributed equally to this work.
* gkrystal@bccrc.ca

Abstract

In previous studies we found that macrophages (MΦs) from SH2-containing inositol-5'-phosphatase (SHIP) deficient mice are M2 polarized while their wild type (WT) counterparts are M1 polarized and that this difference in MΦ phenotype can be recapitulated during in vitro derivation from bone marrow if mouse plasma (MP), but not fetal calf serum, is added to standard M-CSF-containing cultures. In the current study we investigated the mechanism by which MP skews SHIP-/- but not +/+ MΦs to an M2 phenotype. Our results suggest that SHIP-/- basophils constitutively secrete higher levels of IL-4 than SHIP+/+ basophils and this higher level of IL-4 is sufficient to skew both SHIP+/+ and SHIP-/- MΦs to an M2 phenotype, but only when MP is present to increase the sensitivity of the MΦs to this level of IL-4. MP increases the IL-4 sensitivity of both SHIP+/+ and -/- MΦs not by increasing cell surface IL-4 or CD36 receptor levels, but by triggering the activation of Erk and Akt and the production of ROS, all of which play a critical role in sensitizing MΦs to IL-4-induced M2 skewing. Studies to identify the factor(s) in MP responsible for promoting IL-4-induced M2 skewing suggests that all-trans retinoic acid (ATRA), TGFβ and prostaglandin E₂ (PGE₂) all play a role. Taken together, these results indicate that basophil-secreted IL-4 plays an essential role in M2 skewing and that ATRA, TGFβ and PGE₂ within MP collaborate to dramatically promote M2 skewing by acting directly on MΦs to increase their sensitivity to IL-4.

Introduction

Macrophage (MΦ) activation can be broadly divided into M1, pro-inflammatory, and M2, anti-inflammatory subtypes, both of which can alleviate or promote pathologic states [1,2]. For example, M1 MΦs, play a critical role in fighting infections but, through their release of cytotoxic oxidizing agents, such as nitric oxide (NO), and inflammatory cytokines, have also been...
linked to atherosclerotic progression. M2 MΦs, on the other hand, through their anti-inflammatory and wound-healing properties, play an essential role in tissue repair and prevention of auto-immune disorders but can promote asthma [3] and cancer progression [4,5]. It has also been demonstrated that MΦs can either be immune-activating or immune-suppressing, depending on their activation state, and that reducing M2 MΦs and inducing M1 activation improves the prognosis of various cancers in mouse models [4,6–8].

Unlike classically activated M1 MΦs, which are typically activated by microbial components like lipopolysaccharide (LPS) and inflammatory cytokines like interferon γ (IFNγ), alternatively activated M2 MΦs, which promote humoral and/or anti-inflammatory programs [2,9], are very heterogeneous and their specific phenotype appears to be determined by their cytokine milieu. For example, IL-4-stimulated MΦs, currently classified as M(IL-4) MΦs [10], have a distinct phenotype from immune-complex plus TLR ligand-stimulated MΦs or IL-10 and TGF-β polarized M2 MΦs [2,3,9]. Although the growth factors, cytokines, and activating factors responsible for MΦ development and polarization have been identified to some extent [1,2,11], much of the cell-cell interactions and support pathways contributing to both homeostatic and inflammatory MΦ phenotypes have not been fully elucidated.

In previous studies we showed that the hematopoietic cell-restricted negative regulator of phosphatidylinositol 3-kinase (PI3K), SH2-containing inositol 5'-phosphatase (SHIP, also called SHIP1), represses M2 MΦ generation [12]. Specifically, we found that peritoneal and alveolar MΦs in SHIP-/- C57BL/6 mice are polarized towards an M2 phenotype, as indicated by high levels of Arg1 and Ym1 expression as well as low IL-12 and high IL-10 production in response to LPS, while their wild type (SHIP+/+) counterparts are M1 skewed [12–14]. Importantly, not only were peritoneal and alveolar MΦs more M2 polarized in SHIP-/- than SHIP+/+ C57BL/6 mice but tumor associated MΦs (TAMs) were as well, and this correlated with dramatically increased tumor growth rates in SHIP-/- mice [12]. Because of this, we wanted to elucidate the factors responsible for this M2 skewing so that we could prevent/reverse it in vivo to slow tumor growth.

Interestingly, in vitro culturing of SHIP-/- bone marrow (BM) with M-CSF alone, i.e., standard in vitro culture conditions with fetal calf serum (FCS), does not generate M2 MΦs, suggesting this M2 skewing is not an intrinsic property of SHIP-/- MΦ progenitors [12]. However, we can mimic the in vivo differentiation pattern of MΦs in SHIP+/+ (i.e., M1) and SHIP-/- (i.e., M2) by adding mouse plasma (MP) to standard in vitro cultures [12].

More recent studies from our laboratory have implicated basophils as critical players in M2 and Th2 programming in SHIP-/- mice [13,14]. Specifically, we have found that the addition of IL-3 (or GM-CSF to a lesser extent) to BM results in M2 skewing, with resulting SHIP-/- MΦs being more M2 skewed than their SHIP+/+ counterparts. Importantly, we found that IL-3 induces this M2 skewing by stimulating basophils and basophil progenitors to survive, proliferate and secrete IL-4 [14].

Taken together, our results to date suggest that both basophils and MP can play a role in the M2 skewing of SHIP+/+ and SHIP-/- MΦ progenitors. Herein, we have elucidated the roles that MP, IL-3, basophils and IL-4 play in M2 skewing of SHIP+/+ and -/- MΦs and have obtained some insights both into the mechanism by which MP promotes IL-4-induced M2 skewing and the identity of the factors in MP that are responsible.

**Materials and Methods**

**Mice**

SHIP+/+ and SHIP-/- mice on a mixed C57BL/6 × 129Sv background were generated [15] and housed in specific pathogen-free facilities at the British Columbia Cancer Research Centre. All
animal experiments were carried out as described previously [12–14] according to the guidelines for the care and use of animals approved by the University of British Columbia.

Reagents

Mouse plasma (MP) was obtained, using heparin, from a large pool of mixed C57BL/6 × 129Sv background SHIP+/+ mice and one pooled batch was frozen in aliquots and used for all experiments. The following primary mouse-specific antibodies (Abs) were used for Western blotting: anti-Arg1 and anti-Shc (BD Biosciences, Mississauga, ON, Canada), anti-Ym1 (StemCell Technologies, Vancouver, BC, Canada), anti-SHIP and anti-Grb2 (Santa Cruz, Santa Cruz, CA, USA), anti-GAPDH (Fitzgerald Industries International, Acton, MA, USA), anti-AKT, anti-phospho-AKT (Ser473) (Santa Cruz, Santa Cruz, CA, USA), anti-ERK and anti-phospho-ERK (Thr202/Tyr204) (Cell Signaling Technology, Danvers, MA, USA).

For flow cytometric analyses, recommended Ab/cell ratios were used as outlined in specific data sheets. The following fluorochrome-conjugated Abs were used: anti-CD36-APC (eBioscience, San Diego, CA, USA), anti-IL-4Rα-PE (BD Bioscience) and anti-CD49b-APC (clone DX5) (BioLegend, San Diego, CA, USA). Mouse-specific anti-CD16/CD32 (clone 2.4g2) (BD Biosciences), was used to prevent binding of Abs via their Fc regions to IgG receptors on MФs or other cells. Neutralizing Abs to IL-4 and IL-3 (R&D Systems, Minneapolis, MN, USA) were used in M2-skewing assays with MФs and reagent grade mouse IgG (Sigma-Aldrich, Oakville, ON, Canada) was used as an irrelevant control Ab.

All cytokines were purchased from StemCell Technologies except TGFβ1 (R&D Systems). The following agents tested in M2 skewing assays were purchased from Sigma-Aldrich and stock solutions were prepared as indicated: N-acetylcysteine (NAC) (0.5 M freshly prepared in IMDM), rotenone (1 mM in DMSO), BSO (100 mM freshly prepared in distilled water), DTT (100 mM in distilled water), etomoxir, an inhibitor of fatty acid oxidation (FAO) (100 μM), SB-505124, the TGFβ signaling inhibitor (15 mM in DMSO) and Prostaglandin E2 (PGE2) (2.5 mM in PBS). The following were also tested: all-trans retinoic acid (ATRA) (10 mM in ETOH) and LY294002 (10 mM in DMSO) from EMD Millipore (Etobicoke, ON, Canada), U0126 (10 mM in DMSO) from Cell Signaling Technology, the COX-2 inhibitors SC-58125 (13 mM in EtOH) from Cayman Chemical (Ann Arbor, MI, USA) and celecoxib (100 mM in DMSO) from LC Laboratories (Woburn, MA, USA) and the ATRA inhibitor (a selective RARα antagonist), BMS195614 (BMS) (10 mM in DMSO) from Tocris Biosciences (Minneapolis, MN, USA). Mouse-specific IL-4 ELISA kits were purchased from BD Biosciences.

Western analysis

To determine protein concentrations, samples were first solubilized in NP-40 lysis buffer and protein levels assessed using a BCA protein assay kit (Thermo Fisher, Ottawa, ON). Cell lysates, supplemented with concentrated SDS sample buffer to give 1 x SDS sample buffer were boiled for 5 min and subjected to Western analysis as described previously [16].

Derivation of bone marrow macrophages (progenitor assay)

BM was flushed from tibias and femurs, suspended at 25 mL/mouse BM in MФ medium, i.e., IMDM + 10% fetal calf serum (FCS) (Hyclone; South Logan, UT, USA) + 150 μM monothioglycerol (Sigma-Aldrich) + 100 U/mL penicillin + 100 μg/mL streptomycin (P/S), seeded into tissue culture flasks (75cm2) and cultured at 37˚C for 3–18 h. Non-adherent BM progenitors were then harvested and mature BMMΦs derived by culturing 0.5 x 106 cells/mL in MΦ medium with 5–10 ng/mL macrophage colony stimulating factor (M-CSF) (Stemcell
Technologies Inc) +/- 5% MP for 6–14 days with medium changes every 3–4 days, which involved spinning down non-adherent cells and reincorporating them back into the culture as necessary.

Mature macrophage skewing assay
After deriving the MΦs for 6–14 days as described above in large tissue culture flasks (175 cm²), the medium, along with any remaining suspended cells, was aspirated and discarded. To detach the mature MΦs, 10 mL of Accutase (Stemcell Technologies Inc) was added to the flask and incubated for 10 min at 23˚C with agitation. Detached MΦs were pelleted (300 x g) and resuspended to the desired concentration in MΦ medium containing 5–10 ng/ml M-CSF and 200,000 to 400,000 cells were seeded per well into 12 well plates. The macrophages were then treated with the desired skewing agents and/or inhibitors.

For transwell studies, transwell plates (0.4 μm membrane pore size) were purchased from Corning (Lowell, MA, USA). The ratio of basophils (DX5+ cells) (in the top insert) to basophil-depleted progenitors (DX5- progenitors) (bottom well) was 1:10 for all assays.

Harvesting of macrophages
MΦs were harvested using cell dissociation buffer (CDB) (Life Technologies). Before CDB treatment, the medium was aspirated and adherent cells washed with MΦ medium to remove non-adherent cells. After 3–5 min of incubation at 23˚C, cell flasks or dishes were agitated to obtain single-cell suspensions. Cells were lysed directly in SDS-lysis buffer or with 0.5% NP40 (EMD Millipore) for protein quantification before SDS lysis.

Peritoneal macrophage isolation
MΦ medium (5 ml) was injected a total of 3 times into and aspirated out of the peritoneal cavity of a euthanized mouse. MΦs were counted with a hemocytometer, discriminating them from other cells by size and morphology. To adherence select for peritoneal MΦs, cells were plated at 0.5–1.0 x 10⁶ cells/mL for 3 h– 16 h in MΦ medium, after which the wells were washed twice to remove non-adherent cells.

Arginase assay
MΦs were washed with PBS and lysed with arginase lysis buffer (a 1:1 mixture of 0.1% Triton X-100 (Sigma-Aldrich) and 25 mM Tris-HCl, pH 8.0). Using 100 μL of cell lysate, or a dilution of the lysate up to 100 μL with the same buffer, arginase activity was determined by a colorimetric enzyme assay as described by Morrison and Correll [17]. Briefly, each sample was heat-activated at 55˚C for 10 min with 10 μL of 10 mM MnCl₂. Then, 100 μL 0.5 M L-arginine (pH 9.8) (Sigma-Aldrich) was added and incubated at 37˚C for 1 h. The reaction was stopped using 800 μL of a 1:3:7 H₂SO₄:H₃PO₄:H₂O (Fisher). The level of urea was measured by adding 40 μL 9% α-isonitrosopropiophenone (Sigma-Aldrich) (w/v in ethanol (ETOH)) and heating at 100˚C for 30 min. Urea concentration was determined by reading the absorbance at 550 nm and comparing it to a urea standard curve. Arginase activity was expressed as μg urea/μg protein/h. Protein concentration was determined using the Bradford Assay (BioRad; Mississauga, ON, Canada).

Basophil isolation and culture
Mature basophils were enriched from BM using EasySep (StemCell Technologies) and APC-conjugated DX5 Ab at 2–5 μg/mL (BioLegend; San Diego, CA, USA) to positively select for
CD49b+ cells. Basophil function was assessed at a cell concentration of 2–5 x 10^4 cells/100 μL in MΦ medium, unless otherwise stated.

Charcoal stripping, lipid extraction and M-CSF depletion

For charcoal stripping, activated charcoal was added to MP at a concentration of 2g/100mL. The mixture was incubated overnight at 4°C on a rotator. The charcoal was pelleted by centrifugation and the plasma supernatant was collected and filter sterilized.

For lipid extraction the procedure of Cham & Knowles was used [18]. Briefly, two volumes of butanol/di-isopropyl ether (40:60, v/v) were added to one volume of MP containing 0.5 mg/mL EDTA and rotated at 23°C for 30 min. The mixture was centrifuged at 2000 rpm for 5 min in a Beckman Coulter Allegro X-12R centrifuge and the aqueous phase removed with a needle and syringe and then washed one time with 2 volumes of di-isopropyl ether. Both the delipidated aqueous phase and the solvent phase containing the lipid fraction were left to evaporate overnight to remove any residual solvent. The next day the dried lipid fraction was re-suspended in methanol and speed-vacuumed for 1 h and re-suspended in methanol as a 10x.

Statistical analysis

Statistical analyses were performed between SHIP+/+ and -/- samples using the Student’s t-test. As well, data presented in bar graphs were tested using both the student’s t-test and the non-parametric Mann Whitney rank test. Both tests yielded the same results in terms of significance. Thus significant results were obtained in these studies regardless of whether normal distribution was assumed. A confidence level of p < 0.05 was considered significant. Results shown are representative of a minimum of 3 experiments, containing 3 replicates/experiment, unless otherwise stated.

Results

MP-induced M2 polarization of SHIP-/− MΦs involves basophils and IL-4 but not IL-3

In earlier studies we showed that MΦs isolated from the peritoneal cavity or lungs of SHIP-/− C57BL/6 mice are M2 skewed (i.e. express both Arg1 and Ym1 and produce low IL-12 and high IL-10 following LPS stimulation) while WT littermate MΦs are not [12]. However, we could not mimic this in vivo generated difference with standard in vitro BM cultures (i.e., with M-CSF + 10% FCS) (Fig 1A) or with IL-3, which we found skews both SHIP+/+ and -/- progenitors to an M2 phenotype (Fig 1A). On the other hand, we could recapitulate our in vivo findings if we added mouse plasma (5% MP) to our in vitro BM cultures (Fig 1A and [12]). We also found in earlier studies that IL-3 skews both SHIP+/+ and -/- BM progenitors to an M2 phenotype via its stimulation of IL-4 from basophils [13,14]. To determine if MP-induced M2 skewing of SHIP-/− MΦ progenitors was dependent on IL-4, we added a neutralizing anti-IL-4 Ab to both MP- and IL-3-treated SHIP-/− BMMΦ cultures. As expected, given our earlier results [14], the neutralizing Ab to IL-4 modestly reduced IL-3-induced M2-skewing. However, it reduced MP-induced M2-skewing to a far greater extent, as indicated by a more profound reduction in arginase activity (Fig 1B) and Ym1 protein expression (Fig 1C), confirming the involvement of IL-4 in MP-induced M2 skewing.

To look at the role of basophils in MP-induced M2 skewing, SHIP-/− BM was depleted of basophils using the monoclonal Ab, DX5, specific for the cell surface marker CD49b, expressed on basophils. As shown in Fig 1D, basophil-depleted (i.e. DX5- SHIP-/− BM progenitors were incapable of being skewed to an M2 MΦ phenotype with MP unless they were reconstituted...
Fig 1. MP-induced M2 skewing of SHIP-/- BM progenitors requires IL-4 and basophils but not IL-3. 

A) Western blots of MΦs derived from BM for 6 days with M-CSF ± IL-3 (10 ng/mL) or MP (5%).

B) Arginase activity of MΦs from SHIP-/- BM derived for 6 days with 10 ng/mL M-CSF ± IL-3 (10 ng/mL) or MP (5%) with 2.5 μg/mL of either an irrelevant or IL-4-neutralizing Ab. Data (mean ± SD) are representative of 3 independent experiments performed in triplicate. * p < 0.05 compared to all other conditions.

C) Western blot of SHIP-/- MΦs from (B) probed for Ym1, using SHC as a loading control. Dashed lines indicate where irrelevant lanes have been cropped out. All lanes are part of the same time-exposed film on the same gel.

D) Western blot of SHIP-/- BM

E) Arginase activity of SHIP-/- MΦs derived from BM for 6 days with M-CSF ± MP (5%) or IL-3 (10 ng/mL) ± neutralizing Ab to IL-3 (2.5 μg/mL) or IL-4 (2.5 μg/mL).

F) Western blot of cells corresponding to panel (E). *** p < 0.001 compared to relevant control.

doi:10.1371/journal.pone.0168072.g001
with basophils (DX5+ cells). Similarly, SHIP+/+ or -/- DX5- BM was incapable of being skewed to an M2 MΦ phenotype with IL-3 unless they were reconstituted with basophils (data not shown). This is consistent with our earlier finding that only DX5+ BM cells secrete IL-4 in response to IL-3 [13]. While the use of anti-FcεRI, in conjunction with DX5, would give a more highly purified population of basophils, we did not want to risk FcεRI-mediated activation through the use of an Ab, such as MAR-1, because that would elicit IL-4 secretion, which would confound our results [19,20]. Instead, we used DX5 alone to purify basophils even though it is also expressed on NKT and memory T cells in BM [21,22]. However, preliminary studies in which we enriched these T cells subsets, using anti-CD4, from SHIP-/- BM revealed that they did not produce detectable IL-4 in response to IL-3 or MP (data not shown). We therefore conclude that the DX5+ cells contributing to IL-4 production are, indeed, basophils.

We next asked if MP-induced M2-skewing was dependent on IL-3, using a neutralizing Ab to IL-3 and found that while this anti-IL-3 Ab markedly reduced IL-3-induced M2 skewing, as expected, it had no effect on MP-induced M2 skewing. This was shown via arginase activity measurements (Fig 1E) and Western blotting with Abs to Arg1 and Ym1 proteins (Fig 1F). Thus, MP induces M2 skewing of SHIP-/- BM via an IL-4 but not an IL-3 mediated process.

MP acts directly on MΦs to markedly increase their sensitivity to IL-4-induced M2 polarization

To further address the mechanism through which MP selectively M2-skews SHIP-/- but not SHIP+/+ BM progenitors we first asked if MP was acting on the SHIP-/- basophils to trigger more IL-4 production. Specifically, we stimulated SHIP+/+ and SHIP-/- basophils (ie, DX5+ cells) with MP, and discovered that, unlike IL-3, MP did not increase IL-4 production from SHIP-/- basophils, compared to unstimulated SHIP-/- basophils (Fig 2A). Thus, although MP was causing SHIP-/- MΦs to become M2 skewed it was not doing so by increasing IL-4 secretion from SHIP-/- basophils. Importantly, however, SHIP-/- basophils constitutively produced substantially more IL-4 than their SHIP+/+ counterparts (Fig 2A). Also of note, MP significantly increased IL-4 production from SHIP+/+ basophils although the level was still less than SHIP-/- basophils secreted in the absence of stimulation.

Despite the lack of an increase in IL-4 production in MP-stimulated basophils, SHIP-/- BMMΦs derived from MP-stimulated BM were M2-skewed while without MP, they were not (Fig 2B). Since MP skewed to an M2 phenotype in an IL-4-dependent manner, but did not do it through increasing IL-4 levels from basophils, we asked if MP was simply increasing the IL-4 sensitivity of MΦs. To test this we cultured SHIP+/+ and -/- BM-derived mature MΦs (which are adherence selected and thus devoid of basophils and other non-MΦ cell types) or BM progenitors with low levels of IL-4 (0.5 ng/ml) in the presence and absence of MP. As shown in Fig 2C and 2D, the addition of MP markedly enhanced the sensitivity of both mature SHIP+/+ and -/- BMMΦs and BM progenitors to IL-4-induced M2-skewing.

Importantly, these results suggested that SHIP-/- BM-derived MΦs were not more sensitive than SHIP+/+ MΦs to IL-4 or to MP-induced sensitization by IL-4. We therefore hypothesized that SHIP-/- but not SHIP+/+ BM becomes M2-skewed by MP because SHIP-/- BM basophils constitutively produce enough IL-4 to M2 skew but only if MP is present to enhance the response to what would otherwise be an insufficient level of IL-4. To test this, we used a transwell system, co-incubating SHIP+/+ and -/- basophils (DX5+ cells) with basophil-depleted (DX5-) BM progenitor cells or mature, pure BMMΦs. Confirming our hypothesis, both SHIP+/+ and SHIP-/- BMMΦs derived with SHIP-/- basophils were M2-skewed with MP, while those derived either without basophils or with SHIP+/+ basophils failed to robustly M2-skew, even in the presence of MP (Fig 2E). Thus SHIP+/+ and SHIP-/- MΦs are not
Fig 2. MP increases the sensitivity of macrophages to IL-4-induced M2 skewing. A) IL-4 levels secreted by basophils cultured at $5 \times 10^5$ cells/mL for 24 h ± 5% MP or 10 ng/mL IL-3. Addition of DX5 Ab does not stimulate IL-4 production from SHIP-/- BM (data not shown). B) Arginase activity of mature MΦs from the same BM used in panel (A) after 6 days of culture. All results (mean ± SD) are representative of 3 independent experiments. Black arrows indicate ATRA, TGFβ and PGE2 Promote IL-4-Induced M2 MΦ Polarization.
MP enhances IL-4-induced M2 polarization via ROS and activation of Erk and Akt in both SHIP+/+ and -/- MΦs

To gain some insight into how MP was acting directly on the SHIP+/+ and -/- MΦs to enhance IL-4-induced M2 skewing, we first asked if it was simply increasing IL-4 receptor levels on these cells since TGFβ, a factor in MP that we have shown previously plays a role in M2 skewing (Rauh et al), has been reported to increase IL-4Rα levels in mouse microglia [23]. As shown in Fig 3A, this was not the case. After 48 h of incubation, IL-4, at 10 ng/ml, reduced IL-4Rα levels, as expected, but MP or MP + 0.5 ng/ml IL-4 had no effect. Next, since Feng et al showed that M2 polarization is dependent on fatty acid oxidation (FAO) and that the expression of CD36, a receptor for the endocytosis of triacylglycerol-rich lipoprotein particles is induced in MΦs by IL-4 [24], we asked if MP-induced M2 skewing involved FAO or increased CD36 expression. As shown in Fig 3B, MP-induced M2 skewing was unaffected by the FAO inhibitor, etomoxir, and CD36 levels were not enhanced (S1 Fig) suggesting MP was not enhancing M2 skewing via increasing FAO.

We then looked at the signaling pathways triggered by FCS, MP, IL-4 and MP + IL-4. We found that IL-4, but not MP or FCS, increased STAT6 phosphorylation, as expected [25] (Fig 3C). On the other hand, MP potently stimulated the phosphorylation of Erk and Akt while FCS (which does not M2 skew) was far less potent, and IL-4 did not trigger Erk phosphorylation at all but did stimulate Akt phosphorylation, albeit with slower kinetics than MP. Adding IL-4 to MP did not increase the phosphorylation of these two signaling proteins. Our finding that FCS was far less effective than MP at activating Erk and Akt suggested that these two signaling proteins might be involved in M2 skewing. To test this we examined M2 skewing by MP in the presence and absence of the MEK inhibitor U0126 and the PI3K inhibitor, LY294002, and found they both dramatically reduced M2 skewing (Fig 3D), at levels that had a negligible effect on viability (data not shown). Similar results were obtained with wortmannin [12]. Since a recent study showed that ROS plays a critical role in the differentiation of human monocytes to M2 skewed macrophages [26] we then asked if M2 skewing could be suppressed by the ROS scavenger, N-acetyl cysteine (NAC) and/or enhanced by the mitochondrial poison, rotenone, which increases ROS [27], and this indeed was the case (Fig 3E). This suggested that mitochondrial derived ROS may play a critical role in MP-induced M2 skewing, perhaps by directly activating Akt [28] and by inactivating the phosphatases that dephosphorylate Erk [29]. Consistent with ROS playing a role we also found the reducing agent dithiothreitol (DTT) inhibited M2 skewing and L-buthionine-S,R-sulfoximine (BSO), the γ glutamyl cysteine synthetase inhibitor (which depletes GSH and thus increases ROS [30], increased M2 skewing (Fig 3F).
Fig 3. MP enhances IL-4-induced M2 skewing via ROS and activation of Erk andAkt in MΦs. A) Surface IL-4R expression on WT MΦs cultured for 48 h ± 10 ng/mL IL-4, 5% MP, or 5% MP + 0.5 ng/mL IL-4, as assessed by FACS using PE-conjugated anti-IL-4Rα. B) Western blot of WT MΦs exposed to 5% MP ± etomoxir (100 μM) ± 0.5 ng/mL IL-4 for 72 h and probed for Arg1. Grb2 was used as a loading control. C) Western blot of WT MΦs treated or not with 10% FCS, 5% MP ± 0.5 ng/mL or 10 ng/mL IL-4 for 5, 15, 30 or 60 min. The blot was probed for pSTAT6, pAKT, pERK1/2 and ERK1/2. Grb2 was used as a loading control. D)
Identification of the factor(s) in MP responsible for enhancing IL-4-induced M2 polarization of MФs

In earlier studies we established, using bead-bound antibodies to TGFβ and IL-10 to deplete them from MP, that TGFβ but not IL-10, was involved in MP-induced M2-skewing [12]. To pursue this further we tested the TGFβ pathway-specific inhibitor, SB-505124, (which inhibits the TGFβ type 1 receptor activin receptor-like kinases (ALK) 4, 5 and 7 [31]), and found that it significantly reduced MP plus IL-4-induced M2-skewing of both SHIP+/+ and -/- MФs (Fig 4A). Since this only partially blocked M2-induced skewing we attempted several fractionation procedures with MP to identify other factors that might be involved and found that charcoal stripping markedly reduced the M2 skewing ability of MP (Fig 4B). This suggested that a lipid soluble factor might be involved and we pursued this further by performing a gentle lipid extraction which retains proteins in the aqueous phase in their native conformation [18] and found that, indeed, substantial M2 skewing activity was present in the lipid fraction (Fig 4C). Since the lipid soluble prostaglandin, PGE2, has been reported to be involved in M2 skewing [32,33] we then tested it with and without TGFβ. As shown in Fig 4D, TGFβ plus PGE2 acted synergistically to enhance M2 skewing but even at levels substantially higher than that observed physiologically [34,35], they were far less potent than 5% MP at M2 skewing.

Since the lipid soluble vitamin A metabolite, ATRA, has also recently been reported to play a role in M2 skewing [36], we then tested it in lieu of MP for its M2 skewing ability and found that it was indeed a potent M2 skewing factor, triggering substantial Arg1 expression at concentrations as low as 1 nM. Importantly, like MP, it had no M2 skewing ability in the absence of low levels of IL-4 (Fig 4E).

We then tested the combination of ATRA, TGFβ and PGE2, at levels reported to be present in MP [34,35] for their ability to M2 skew and found that, together, they elicited Arg1 levels similar to that of 5% MP (Fig 4F). Also, the ability of the combination of ATRA, TGFβ and PGE2 to M2 skew was markedly inhibited by the inhibitors, NAC, U0126 and LY294002 (Fig 4F), mimicking the response of MP to these agents. As well, using specific inhibitors of each of them, i.e., BMS195614 (BMS) for ATRA (a selective RARα antagonist) [37], SB-505124 for TGFβ and the COX2 inhibitor, SC-58125, for PGE2 we found that, as expected, they totally eradicated M2 skewing.

Lastly, to determine if ATRA, TGFβ, and PGE2 actually participated in MP-induced M2 skewing, we tested BMS, SB-505124 and SC-58125, at the same concentrations used to treat ATRA, TGFβ and PGE2, to see if they reduced the M2 skewing capacity of MP. As shown in Fig 4G, each inhibitor alone significantly reduced the M2 skewing capacity of MP but, more importantly, addition of all 3 inhibitors reduced M2 skewing of MP to baseline levels achieved with low levels of IL-4 alone.

Discussion

In order to evaluate, in vitro, potential therapeutic agents for their efficacy in skewing MФs to an M1 or M2 phenotype it is important to use culture conditions that mimic, as closely as possible, in vivo conditions. Our studies strongly suggest that the standard culture conditions
Fig 4. Identification of the factors in MP responsible for enhancing IL-4-induced M2 skewing of MΦs. A) Western blot of mature SHIP+/+ and -/- MΦs stimulated for 72 h with 5% MP + 0.5 ng/mL IL-4 ± nothing (C), vehicle control (DMSO) (V) or 1 μM of the TGFβ inhibitor, SB505124. B) Western blot showing the effect of charcoal stripping (CS) on the ability of MP to induce M2 skewing WT MΦs in the presence of 0.5 ng/mL IL-4 compared to intact MP. C) Western blot showing the effects of MP delipidation (DL MP) and the recovered lipid fraction (Lip Fx) on the ability to M2 skew WT MΦs in the presence of 0.5 ng/mL IL-4. D) Arginase activity of SHIP-/- BM MΦs derived with increasing doses of TGFβ and PGE2. All data points are the mean ± SEM of experimental triplicates of 2 independent experiments. E) Western blot showing the effect of an ATRA dose response ± 0.5 ng/mL IL-4 on M2 skewing of mature WT MΦs after culture for 48 h. F) Western blot showing the effect of the combination of 5 μM BMS, 1 μM SB505124 and 20 μM SC28125 as well as 3 mM NAC, 5 μM UO126, and 5 μM LY294002 on ATRA (4 nM) + TGFβ (2 ng/mL) + PGE2 (3 ng/mL) induced M2 skewing of WT MΦs ± 0.5 ng/mL IL-4 after 48 h in culture. G) Western blot showing the effect of BMS SB505124 and SC58125 at the same concentrations as in (F) and the combination of all three on MP-induced M2 skewing of WT MΦs ± 0.5 ng/mL IL-4 after 48 hr in culture. For panels C, F and G, densitometry was performed and expression levels of Arg1, relative to Grb2 levels, are indicated. All results are representative of 2 or 3 independent experiments.

doi:10.1371/journal.pone.0168072.g004
used for both the derivation of murine MΦs from BM and the skewing of mature MΦs (i.e. 10% FCS + 5–10 ng/ml M-CSF) do not reflect the in vivo environment and that the addition of 5% MP brings it more into line with what is happening in vivo, at least with regard to the M1 and M2 skewing of SHIP+/+ and -/- BM MΦs. Specifically, the addition of 5% MP not only increases the expression of Arg1 and Ym1 but TGFβ and IL-10 as well and MP also leads to the reduced synthesis of M1 markers (TNFα, CCL3 and NO) in response to LPS [12].

Related to this, we found that, in addition to MP, both human serum and human plasma M2 skew as well. Also, unlike FCS, calf serum M2 skews, suggesting that fetal serum lacks factors that promote (or possess factors that inhibit) M2 skewing. Using these new culture conditions has allowed us to elucidate, to some extent, the factors responsible for the M2 skewing of both WT and SHIP-/− BM MΦs under homeostatic (i.e. uninfected) conditions in the mouse. Using both 6 day assay cultures, with SHIP+/+ and -/- murine BM depleted of mature MΦs (adherent cells) to see the effects of basophils, IL-4, etc during differentiation, and mature BM-derived MΦs to look at factors that affect the skewing of mature MΦs toward an M1 or M2 phenotype, we have obtained evidence that MP pushes both towards an M2 phenotype if a low but necessary level of IL-4 is present to support this skewing.

Specifically, our results suggest a model for M2 MΦ skewing (see Fig 5) in which basophils play a central role. Basophils that lack SHIP constitutively secrete more IL-4 than WT

Fig 5. Proposed model of M2-skewing of SHIP+/+ and -/- MΦs. SHIP-/−, but not +/+, basophils constitutively secrete sufficient IL-4 to M2 skew SHIP+/+ or -/- progenitors or mature MΦs but only in the presence of ATRA, TGFβ and PGE2 in MP. These MP factors synergize with low levels of IL-4 to M2 skew the MΦs under non-inflamed conditions.

doi:10.1371/journal.pone.0168072.g005
basophils as one might expect given that IL-4 production has been shown to be PI3K dependent [13,14]. In the presence of MP there is approximately 2 to 10 fold (data not shown) more IL-4 secreted/cell from SHIP−/− than SHIP+/+ basophils. Compounding this difference, SHIP−/− mice suffer from basophilia and have 2–3 fold more basophils in their BM and peripheral blood [13]. However, this level of IL-4 is still insufficient to skew MΦs to an M2 phenotype in the absence of MP. Importantly, while SHIP−/− basophils produce more IL-4 than WT basophils, our transwell experiments highlight the ability of SHIP+/+ basophils to M2-skew MΦ to M2-ske and the only reason WT MΦs are not M2 skewed during differentiation is because WT basophils produce less IL-4 than SHIP−/− basophils and that if adequate IL-4 is provided, both WT and SHIP−/− MΦs will be M2 skewed to the same extent when incubated with MP. Of note, in these transwell studies, SHIP−/− basophils alone were capable of M2-skewing MΦs, suggesting that, given sufficient numbers, basophils through their PI3K activation status and trafficking, are likely important mediators of M2 skewing in general and not just in the perturbed, SHIP−/− mouse.

To elucidate how MP promotes M2 skewing we carried out mechanism of action studies and found that MP was not promoting M2 skewing by further activating basophils but rather by acting directly on MΦ but rather by heir responsiveness to IL-4. This increased responsiveness does not appear to be mediated via either increased cell surface IL-4Rs on MΦ (in contrast to recent studies showing that TGFβ enhances M2-like skewing of murine microglia by upregulating IL-4Rα levels [23]) or by increasing FAO (in contrast to recent elegant studies from the Pearce lab showing that M2 MΦ polarization is dependent on FAO and is accompanied by an increase in cell surface expression of CD36, a receptor involved in taking up triacylglycerol-rich lipoprotein particles [24]). On the contrary, our results, using NAC, DTT, rotenone, BSO, U0126 and LY294002 are consistent with MP enhancing IL-4-induced M2-skewing via mitochondrial ROS production. This is interesting since ROS have traditionally been associated with M1 MΦ and M2 skewing as well [26,39]. ROS, in turn, is capable of activating Akt [28] and preventing the deactivation of the Erk pathway (via ROS-induced inactivation of deactivating phosphatases [29,40]). However, a caveat to this model is that, after carrying out many experiments with both dihydroethidium (DHE) and 2',7’–dichlorofluorescin diacetate (DCFDA) to stain ROS, we only obtained a non-statistically significant trend towards increased ROS in MΦs. This may have been due to rapid reduction of ROS to maintain Erk phosphorylation.

Our studies to characterize the specific factors in MP that are responsible for increasing the sensitivity of MΦs suggest that TGFβ, which we have shown previously to play a role in MP-induced M2 skewing [12], collaborates with ATRA and PGE2 in MP to sensitize MΦs to IL-4-induced M2 skewing. Our findings with ATRA are in agreement with a recent report showing that ATRA, while having no effect on its own, dramatically potentiates IL-4-induced Arg 1 in BM-derived mouse MΦs [36]. Also of note, since PGE2 has a half-life in plasma of only 30 sec, the inhibition of MP-induced M2 skewing that we observe with the COX2 inhibitors SC58125 (Fig 4F) and celecoxib (data not shown), are likely due to blocking of PGE2 production and its autocrine effects on our MΦs. Related to this, both ATRA and TGFβ, and likely other factors in MP, appear to stimulate the production of PGE2 [41,42]. Both mice and humans have been shown to display a wide spectrum of M1 to M2 skewing under unchallenged (homeostatic) conditions and this, in turn, has been shown to have a profound influence on their ability to fight off infections and prevent various disorders [43,44].
growth by skewing the immune system to a "healing" M2 phenotype and we as well as many others have shown that you can prevent as well as slow down the growth of many tumours with COX2 inhibitors [45]. As well, since atherosclerosis is promoted by M1 macrophages [46] and asthma and allergies are worsened by M2 skewed macrophages, reducing ATRA, PGE2 and/or TGFβ may prove efficacious in reducing the symptoms of allergies, asthma and the incidence and progression of cancer while increasing these factors might reduce certain forms of heart disease.

While many molecules have been reported to be capable of M1 and M2 skewing [43,44], there is very little evidence to date on which factors in plasma actually play a role. Interestingly, ATRA, TGFβ and PGE2 are distinct from the well-established M2-skewing factors known to be involved during inflammation (e.g. IL-3, IgE + Ag). Based on our results we hypothesize that under homeostatic, unchallenged conditions where IL-3 and IgE + Ag are not major players in MΦ polarization, ATRA, TGFβ and PGE2 likely play a significant role in M2 skewing. This is supported by our IL-3 neutralization experiments demonstrating that IL-3 itself does not play a role in MP-mediated M2-skewing under homeostatic conditions. However, it is likely that many other factors, such as IL-6 [32], IgG immune complexes [47], etc, also play a role. Under inflammatory conditions where IL-3 levels are elevated or when allergen inducing IgE triggering occurs on basophils, sufficient IL-4 is secreted from both SHIP+/+ and -/- basophils to trigger M2 MΦ skewing in the absence of these MP factors.

With regard to the regulation of ATRA, TGFβ and PGE2 levels in human plasma, ATRA levels have been shown to be impacted by both diet [48] and genetics (via the enzymes that generate it from vitamin A (retinol) and degrade it [49]). TGFβ levels, on the other hand, are regulated in large part by release from inhibitory binding proteins in tissues and plasma and from activated platelets. Also, it, as well as PGE2, is often secreted by human tumor cells to repress anti-tumor immunity [50,51].

In summary, our studies suggest that ATRA, PGE2 and TGFβ within MP all play a significant role in M2 skewing in vivo and may serve as an additional microenvironmental stimulus for M2 skewing when IL-4 levels are low. This makes them, together with SHIP [38], attractive targets for either the induction or suppression of M2-polarization, depending on the disorder to be treated.

Supporting Information

S1 Fig. Cell surface CD36 levels are not enhanced on MΦs in response to MP. Surface CD36 expression on SHIP+/+ MΦs cultured for 48 h ± 10 ng/mL IL-4, 5% MP, or 5% MP + 0.5 ng/mL IL-4, as assessed by FACS. (TIF)

Author Contributions

Conceptualization: VWH GK.
Data curation: VWH.
Investigation: VWH EH IE VL BEH JL BL.
Supervision: IE IS GK.
Writing – original draft: VWH.
Writing – review & editing: GK.
References

1. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002; 23: 549–55. PMID: 12401408

2. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol. 2008; 8: 958–69. doi: 10.1038/nri2448 PMID: 19029990

3. Boorsma CE, Draijer C, Melgert BN. Macrophage heterogeneity in respiratory diseases. Mediators Inflamm. 2013; 2013: 769214. doi: 10.1155/2013/769214 PMID: 23533311

4. Galdiero MR, Garlanda C, Jaillon S, Marone G, Mantovani A. Tumor associated macrophages and neutrophils in tumor progression. J Cell Physiol. 2012; 228: 1404–12.

5. Salagianni M, Galani IE, Lundberg AM, Davos CH, Varela A, Gavril A, et al. Toll-like receptor 7 protects from atherosclerosis by constraining "inflammatory" macrophage activation. Circulation. 2012; 126: 952–62. doi: 10.1161/CIRCULATIONAHA.111.067678 PMID: 22787112

6. Desmedt M, Rottiers P, Dooms H, Grooten J. Macrophages induce cellular immunity by activating Th1 cell responses and suppressing Th2 cell responses. J Immunol. 1998; 160: 5300–8. PMID: 9605128

7. Hamilton MJ, Antignano F, Von Rossum A, Boucher J-L, Bennewith KL, Krystal G. TLR agonists that induce IFN-β abrogate resident macrophage suppression of T cells. J Immunol. 2010; 185: 4545–53. doi: 10.4049/jimmunol.1002045 PMID: 20844190

8. Sinha P, Clements VK, Ostrand-Rosenberg S. Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. J Immunol. 2005; 174: 636–45. PMID: 15694881

9. Murray PJ, Allen JE, Biswas SK, Fisher EA, Goerdt S, et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity. 2014; 41: 14–20. doi: 10.1016/j.immuni.2014.06.008 PMID: 25035950

10. Stein M, Keshav S, Harris N, Gordon S. Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. J Exp Med. 1992; 176: 287–92. PMID: 1613462

11. Rauh MJ, Ho V, Pereira C, Sham A, Sly LM, Lam V, et al. SHIP represses the generation of alternatively activated macrophages. Immunity. 2005; 23: 361–74. doi: 10.1016/j.immuni.2005.09.003 PMID: 16226502

12. Kuroda E, Antignano F, Ho VW, Hughes MR, Ruschmann J, Lam V, et al. SHIP represses Th2 skewing by inhibiting IL-4 production from basophils. J Immunol. 2011; 186: 323–32. doi: 10.4049/jimmunol.1002778 PMID: 21131429

13. Kuroda E, Ho V, Ruschmann J, Antignano F, Hamilton M, Rauh MJ, et al. SHIP represses the generation of IL-3-induced M2 macrophages by inhibiting IL-4 production from basophils. J Immunol. 2009; 183: 3652–60. doi: 10.4049/jimmunol.0900864 PMID: 19710468

14. Helgason CD, Damen JE, Rosten P, Grewal R, Sorensen P, Chappell SM, et al. Targeted disruption of SHIP leads to hematopoietic perturbations, lung pathology, and a shortened life span. Genes Dev. 1998; 12: 1610–20. PMID: 9620849

15. Damen JE, Wakao H, Miyajima A, Kros J, Humphries RK, Cutler RL, et al. Tyrosine 343 in the erythropoietin receptor positively regulates erythropoietin-induced cell proliferation and STAT5 activation. EMBO J. 1995; 14: 5557–68. PMID: 8521813

16. Morrison AC, Correll PH. Activation of the stem cell-derived tyrosine kinase/RON receptor tyrosine kinase by macrophage-stimulating protein results in the induction of arginase activity in murine peritoneal macrophages. J Immunol. 2002; 168: 853–60. PMID: 11777982

17. Cham BE, Knowles BR. A solvent system for delipidation of plasma or serum without protein precipitation. J Lipid Res. 1976; 17: 176–81. PMID: 818332

18. Ben Sasson SZ, Le Gros G, Conrad DH, Finkelman FD, Paul WE. Cross-linking Fc receptors stimulate splenic non-B, non-T cells to secrete interleukin 4 and other lymphokines. Proc Natl Acad Sci USA. 1990; 87: 1421–5. PMID: 21061135

19. Denzel A, Maus UA, Rodriguez GM, Moll C, Niedermeier M, Winter C, et al. Basophils enhance immunological memory responses. Nat Immunol. 2008; 9: 733–42. doi: 10.1038/n.1621 PMID: 18516038
21. Han WG, van der Voort EI, el Bannoudi H, Louis-Plence P, Huizinga TW, Toes RE. DX5\(^+\)CD4\(^+\) T cells modulate cytokine production by CD4\(^+\) T cells towards IL-10 via the production of IL-4. Eur J Immunol. 2010; 40: 2731–40. doi: 10.1002/eji.201040574 PMID: 20812238

22. Yoshimoto T, Paul WE. CD4\(^+\), NK1.1\(^+\) T cells promptly produce interleukin 4 in response to in vivo challenge with anti-CD3. J Exp Med. 1994; 179: 1285–95. PMID: 7908323

23. Zhou X, Spittau B, Kriegstein K. TGF\(\beta\) signalling plays an important role in IL4-induced alternative activation of microglia. J Neuroinflammation. 2012; 9: 210. doi: 10.1186/1742-2049-9-210 PMID: 22947253

24. Feng J, Han J, Pearce SF, Silverstein RL, Gotto AM Jr., Hajjar DP, et al. Induction of CD36 expression by oxidized LDL and IL-4 by a common signaling pathway dependent on protein kinase C and PPAR-\(\gamma\)J. Lipid Res. 2000; 41: 688–96.

25. Hebenstreit D, Wirnsberger G, Horejs-Hoeck J, Duschl A. Signaling mechanisms, interaction partners, and target genes of STAT6. Cytokine Growth Factor Rev. 2006; 17: 173–88. doi: 10.1016/j.cytogfr.2006.01.004 PMID: 16540365

26. Zhang Y, Choksi S, Chen K, Pobezinskaya I, Linnoila I, Liu ZG. ROS play a critical role in the differentiation of alternatively activated macrophages and the occurrence of tumor-associated macrophages. Cell Res. 2013; 23: 898–914. doi: 10.1038/cr.2013.75 PMID: 23752925

27. Martinez TN, Greenamyer JT. Toxin models of mitochondrial dysfunction in Parkinson’s disease. Anti-oxid Redox Signal. 2012; 16: 920–34. doi: 10.1089/ars.2011.4033 PMID: 21554057

28. Uschio-Fukai M, Alexander RW, Akers M, Yin Q, Fujio Y, Walsh K, et al. Reactive oxygen species mediate the activation of Akt/protein kinase B by angiotensin II in vascular smooth muscle cells. J Biol Chem. 1999; 274: 22699–704. PMID: 10428852

29. Traore K, Sharma R, Thimmappaya RK, Watson WH, Biswal S, Trush MA. Redox-regulation of Erk1/2-directed phosphatase by reactive oxygen species: role in signaling TPA-induced growth arrest in ML-1 cells. J Cell Physiol. 2008; 216: 276–85. doi: 10.1002/jcp.21403 PMID: 18270969

30. Armstrong JS, Steinauer KK, Homung B, Irish JM, Lecane P, Birrell GW, et al. Role of glutathione depletion and reactive oxygen species generation in apoptotic signaling in a human B lymphoma cell line. Cell Death Differ. 2002; 9: 252–63. doi: 10.1038/sj.cdd.4400959 PMID: 11859408

31. DaCosta Byfield S, Major C, Laping NJ, Roberts AB. SB-505124 is a selective inhibitor of transforming growth factor-beta type I receptors ALK4, ALK5, and ALK7 Mol Pharmacol. 2004; 65: 744–52. doi: 10.1016/S0026-9259(04)00111-X PMID: 14978253

32. Heusinkveld M, de Vos van Steenwijk PJ, Goedemans R, Ramwadhdoebe TH, Gorter A, Welters MJ, et al. M2 macrophages induced by prostaglandin E\(_2\) and IL-6 from cervical carcinoma are switched to activated M1 macrophages by CD4\(^+\) Th1 cells. J Immunol. 2011; 187: 1157–65. doi: 10.4049/jimmunol.1100889 PMID: 21709158

33. Eruslanov E, Daukin I, Vieweg J, Daaka Y, Kusmartsev S. Aberrant PGE\(_2\) metabolism in bladder tumor microenvironment promotes immunosuppressive phenotype of tumor-infiltrating myeloid cells. Int Immunopharmacol. 2011; 11: 848–55. doi: 10.1016/j.intimp.2011.01.033 PMID: 21315786

34. Obropta KM, Kane MA, Napoli JL. Effects of diet and strain on mouse serum and tissue retinoid concentrations. PLoS One. 2014; 9: e999435. doi: 10.1371/journal.pone.0099435 PMID: 24911926

35. Khan SA, Joyce J, Tsuda T. Quantification of active and total transforming growth factor-\(\beta\) BMC Res Notes. 2012; 5: 636. doi: 10.1186/1756-0500-5-636 PMID: 23151377

36. Surace MJ, Li L. Potent suppression of arginase 1 expression in murine macrophages by low dose endotoxin. Am J Clin Exp Immunol. 2013; 2: 117–23. PMID: 23885329

37. Lo HM, Wang SW, Chen CL, Wu PH, Wu WB. Effects of all-trans retinoic acid, retinol, and beta-carotene on murine macrophage activity. Food Funct. 2014; 5: 140–8. doi: 10.1039/c3fo60309a PMID: 24310731

38. Blunt MD, Ward SG. Targeting PI3K isoforms and SHIP in the immune system: new therapeutics for inflammation and leukemia. Curr Opin Pharmacol. 2012; 12: 444–51. doi: 10.1016/j.coph.2012.02.015 PMID: 22483603

39. Brown SD, Brown LA. Ethanol induced TGF-\(\beta\) and ROS production are necessary for ethanol induced alveolar macrophage dysfunction and induction of alternative activation. Alcohol Clin Exp Res. 2012; 36: 1952–62. doi: 10.1111/j.1530-0277.2012.01825.x PMID: 22551312

40. Ostman A, Friijhoff J, Sandin A, Bohmer FD. Regulation of protein tyrosine phosphatases by reversible oxidation. J Biochem. 2011; 150: 345–56. doi: 10.1093/jb/mvr104 PMID: 21856739

41. Mamidi S, Hofer TP, Hoffmann R, Ziegler-Heitbrock L, Frankenberger M. All-trans retinoic acid up-regulates Prostaglandin-E Synthase expression in human macrophages. Immunobiology. 2012; 217: 593–600. doi: 10.1016/j.imbio.2011.10.022 PMID: 22024820
42. Schalkwijk CG, de Vet E, Pfeilschifter J, van den Bosch H. Interleukin-1β and transforming growth factor-β2 enhance cytosolic high-molecular-mass phospholipase A2 activity and induce prostaglandin E2 formation in rat mesangial cells. Eur J Biochem. 1992; 210: 169–76. PMID: 1446669

43. Martinez FO, Gordon S. The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep. 2014; 6: 13. doi: 10.12703/P6-13 PMID: 24669294

44. Rosser T. Understanding the mysterious M2 macrophage through activation markers and effector mechanisms. Mediators Inflamm. 2015; 2015: 816460. doi: 10.1155/2015/816460 PMID: 26089604

45. Ho VW, Hamilton MJ, Dang N-HT, Hsu BE, Adomat HH, Guns ES, et al. A low carbohydrate, high protein diet combined with celecoxib markedly reduces metastasis. Carcinogenesis. 2014; 35: 2291–9. doi: 10.1093/carcin/bgu147 PMID: 25023988

46. Bouhlel MA, Derudas B, Rigamonti E, Dievart R, Brozek J, Haulon S, et al. PPARγ activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metab. 2007; 6: 137–43. doi: 10.1016/j.cmet.2007.06.010 PMID: 17681149

47. Gallo P, Goncalves R, Mosser DM. The influence of IgG density and macrophage Fc (gamma) receptor cross-linking on phagocytosis and IL-10 production. Immunol Lett. 2010; 133: 70–7. doi: 10.1016/j.imlet.2010.07.004 PMID: 20670655

48. Ruhl R, Bub A, Watzl B. Modulation of plasma all-trans retinoic acid concentrations by the consumption of carotenoid-rich vegetables. Nutrition. 2008; 24: 1224–6. doi: 10.1016/j.nut.2008.05.022 PMID: 18653315

49. Guo Y, Brown C, Ortiz C, Noelle RJ. Leukocyte homing, fate, and function are controlled by retinoic acid. Physiol Rev. 2015; 95: 125–48. doi: 10.1152/physrev.00032.2013 PMID: 25540140

50. Eruslanov E, Daurkin I, Ortiz J, Vieweg J, Kusmartsev S. Pivotal advance: Tumor-mediated induction of myeloid-derived suppressor cells and M2-polarized macrophages by altering intracellular PGE2 catabolism in myeloid cells. J Leukoc Biol. 2010; 88: 839–48. doi: 10.1189/jlb.1209821 PMID: 20587738

51. Gorsch SM, Memoli VA, Stukel TA, Gold LI, Arrick BA. Immunohistochemical staining for transforming growth factor β1 associates with disease progression in human breast cancer. Cancer Res. 1992; 52: 6949–52. PMID: 1458485